incretin raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-10-23. Anything still debated is marked as such rather than presented as settled.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
== Applications == Quantitative/qualitative analysis of collective cell migration under changeable experimental conditions. Analysis of cell-matrix and cell-cell interactions with respect to cell migration. High-throughput screens for: Cancer cell migration genes Small molecules Drug discovery
== Background == Following along with the Japanese history textbook controversies and a decline in Sino-Japanese relations, the poem began to circulate over China internet community via forwarded email and internet forums around 2003 to 2004. The circulation peaked during the 2005 anti-Japanese demonstrations. It was quickly revealed that not only does the cadence of the poem fail to match the tradition of Tang poetry, its writing style also differs from that of Li Bai. The archive of Li Bai also does not contain any such poem. The real author is yet to be revealed, but it is believed to be written by a mainland Chinese angered by Japan's denial of World War II war crimes.
At a 2016 meeting with Pope Francis, DiCaprio donated to charity and discussed environmental issues with him. A few days later, possibly influenced by this meeting, the Pope said he would act in a charity film. DiCaprio traveled to Indonesia in early 2016 where he criticized the government's palm oil industry's slash-and-burn forest clearing methods. In July 2016, his foundation donated $15.6 million to help protect wildlife and the rights of Native Americans, along with mitigating climate change. That October, DiCaprio joined Mark Ruffalo in support of the Standing Rock tribe's opposition to the Dakota Access Pipeline. In April 2017, DiCaprio protested against President Donald Trump's inaction on climate change by attending the People's Climate March. In July, a charity auction and celebrity concert arranged by DiCaprio's foundation had raised over $30 million in one night. The DiCaprio foundation donated $100 million in December 2018 to fight climate change. In May 2021, DiCaprio pledged $43 million to enact conservation operations across the Galápagos Islands.
Anti-acetylcholine receptors (anti-AChR) antibodies have also been detected in patients with thymoma, but without clinical manifestations of myasthenia gravis. There have also been reports of non-paraneoplastic limbic encephalitis associated with raised serum VGKC suggesting that these antibodies may give rise to a spectrum of neurological disease presenting with symptoms arising peripherally, centrally, or both. Yet, in two cases, oligoclonal bands were absent in the CSF and serum, and CSF immunoglobulin profiles were unremarkable.
=== Genetic heterogeneity === Historically, "Ca. M. multicellularis" was thought to be entirely clonal due to its synchronous cell division. However, single-consortium metagenome (SCM) sequencing has revealed that the individual cells within each organism are genetically heterogeneous. The constituent cells feature distinct single-nucleotide polymorphisms (SNPs) situated randomly across their genomes.
Sources: en.wikipedia.org
=== South American think tanks === Research done by Enrique Mendizabal shows that South American think tanks play various roles depending on their origins, historical development and relations to other policy actors. In this study, Orazio Bellettini from Grupo FARO suggests that they:
== Overview == Fructilactobacillus sanfranciscensis was first known to be isolated in 1971 by Kline and Sugihara. As lactic acid bacteria, the strains are Gram-positive, slender, rod-shaped, nonsporulating, and non-motile. They are also obligately heterofermentative, meaning that they can convert hexose sugars into not just lactic acid, but also ethanol, CO2, and/or acetic acid. This heterofermentative ability is key for this species' role in creating the unique flavor of sourdough bread. Sourdough starters are leavened by a mixture of yeast and lactobacilli in a ratio of about 1:100. Common yeast species found in combination with F. sanfranciscensis are Kazachstania humilis, Saccharomyces cerevisiae, and Wickerhamomyces anomalus. This yeast cannot metabolize the maltose found in the dough, while the Fructilactobacillus requires maltose. They therefore act without conflict for substrate, with lactobacilli utilizing maltose and the yeast utilizing the other sugars, including the glucose produced by the F. sanfranciscensis.
=== Defense towers === The porte d’Italie was guarded by two towers built to the east of the previous towers of the 4th century BC. The north tower or square tower, 10.50 m (34.4 ft) wide, is attached to the Wall of Crinas. Some internal blocks bear the marks of quarrymen or stonemasons. The south tower is also called the leaning tower, because its eastern facing has collapsed, the ground being formerly marshy. It was also square, 10.30 m (33.8 ft) wide. Only the eastern facing is preserved. It has two loopholes. These two towers, which rose to a height of 12 to 15 meters (39 to 49 ft), framed the porte d’Italie. A 22 m-long (72 ft) curtain wall connected the leaning tower to a rectangular tower (7.8 m × 8.4 m [26 ft × 28 ft]). This curtain wall has been rebuilt to give a better idea of this fortification.
=== Nana Mary === Nana Mary is played by Shelley Winters. Nana Mary is Beverly's mother and Roseanne and Jackie's grandmother, and first appears at a family barbecue in season three. She has another daughter named Sonya. She makes several appearances from season three onward, mostly during family occasions. She is a brash but caring, outspoken, lovable retiree who gambles with her grandchildren. Unlike Bev, she is popular with the family. She also disagrees with Bev in certain situations, such as siding with Jackie when Bev urges her to marry Fred, and revealing that she had two abortions, upsetting Bev. She outsmarts Bev and torments her, much to the amusement of Roseanne and Jackie, who usually endure the same treatment from Bev. Her character is often a comic relief for the family, as well as offering a balance between Roseanne and Jackie's relationship with their mother, and Bev's relationship with Nana Mary. She was promiscuous in her youth and claims that as a globe-trotting free spirit she knew Pablo Picasso, Louis Armstrong, Ernest Hemingway, Fidel Castro, and Meyer Lansky, among others. Mary had Bev with another man before marrying her deceased husband, Marvin. She tells Bev she was very young when she gave birth, admits to not knowing who the father is, and avoided the subject until Bev demanded to finally know. Mary is a fan of a local radio call-in show that revolves around sex: "If I don't call, they worry," she claims.
Sources: en.wikipedia.org
Typically, studies have reported finding no significant levels of Neanderthal DNA in Sub-Saharan Africans, but a 2020 study detected 0.3-0.5% in the genomes of five African sample populations, likely the result of Eurasians back-migrating and interbreeding with Africans, as well as human-to-Neanderthal gene flow from dispersals of Homo sapiens preceding the larger Out-of-Africa migration, and also showed more equal Neanderthal DNA percentages for European and Asian populations. Such low percentages of Neanderthal DNA in all present day populations indicate infrequent past interbreeding, unless interbreeding was more common with a different population of modern humans which did not contribute to the present day gene pool. Of the inherited Neanderthal genome, 25% in modern Europeans and 32% in modern East Asians may be related to viral immunity. In all, approximately 20% of the Neanderthal genome appears to have survived in the modern human gene pool. Due to their small population and resulting reduced effectivity of natural selection, Neanderthals accumulated several weakly harmful mutations, which were introduced to and slowly selected out of the much larger modern human population; the initial hybridised population may have experienced up to a 94% reduction in fitness compared to contemporary humans. By this measure, Neanderthals may have substantially increased in fitness. A 2017 study focusing on archaic genes in Turkey found associations with coeliac disease, malaria severity and Costello syndrome.
The 2021 Copa América, relocated to Brazil at short notice, brought a third-place finish. Colombia beat Ecuador 1–0, drew 0–0 with Venezuela, then lost 2–1 to Peru and 2–1 to Brazil to finish third in Group B on four points. They eliminated Uruguay 4–2 on penalties in the quarter-finals in Brasília, a match in which David Ospina passed Carlos Valderrama's appearance record to become Colombia's most-capped player. Argentina won the semi-final 3–2 on penalties after a 1–1 draw, and Colombia beat Peru 3–2 in the third-place match, Luis Díaz scoring twice to finish as the tournament's joint leading scorer with Lionel Messi on four goals. Qualification for Qatar was lost to a scoring drought spanning seven consecutive matches. Although Colombia beat Venezuela 1–0 in their final fixture, they finished sixth on 23 points, one behind Peru, who took the play-off place. Rueda left shortly afterwards.
== Mechanisms of action == The mechanisms of action of artesunate remains unclear and debatable. Artesunate is a prodrug that is rapidly converted to its active form dihydroartemisinin (DHA). This process involves hydrolysis of the 4-carbon ester group via plasma esterase enzyme. It is hypothesized that the cleavage of endoperoxide bridge in the pharmacophore of DHA generates reactive oxygen species (ROS), which increases oxidative stress and causes malarial protein damage via alkylation. In addition, Artesunate potently inhibits the essential Plasmodium falciparum exported protein 1 (EXP1), a membrane glutathione S-transferase. As a result, the amount of glutathione in the parasite is reduced. In 2016, artemisinin has been shown to bind to a large number targets, suggesting that it acts in a promiscuous manner. There is evidence suggesting DHA inhibition of calcium-dependent ATPase on endoplasmic membrane, which disrupts protein folding of parasites. It has also been reported to target tubulin, favorizing its polymerization.
Sources: en.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
It is a synthetic peptide classified as a triple receptor agonist. It engages the GLP-1, GIP, and glucagon receptors at once. It is investigated for metabolic and weight-related conditions rather than approved for general use.